First-in-human dose study for advanced cancers using AN4005
Part of Cancer clinical trials.
This early study tests AN4005 in adults with advanced or hard-to-treat solid tumors or certain lymphomas. The goal is to find a safe dose and see how the treatment behaves in the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older and able to sign consent.
- Your cancer must be advanced (metastatic or not operable) or have come back, and no standard treatment options work for you.
- You should be well enough for treatment (ECOG performance status 0–1) and expected to live at least 3 months.
- You must have usable tumor tissue from a recent biopsy or archived tissue, and some lymphoma types may need a bone marrow biopsy.
- Your heart function and basic blood and organ tests must be within required limits.
- You must be able to take the study medicine by mouth and follow all study rules.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests the safety and side effects of ABL503 and finds the best dose to study next. It is for people with advanced cancer that is growing despite prior treatment options.
This Phase 1/2 study tests an experimental medicine (RNK05047) in people with advanced solid tumors or diffuse large B‑cell lymphoma whose standard treatments haven’t worked or can’t be tolerated. It may help shrink tumors and improve control of the disease, but early-phase trials also focus on safety and dosing.
This trial tests a new drug, INI-4001, for people with advanced solid tumors that have spread or can't be removed. It aims to see if the drug is safe and effective.
This Phase 1 trial tests BPI-371153, a new treatment, in people with advanced solid tumors or relapsed or refractory lymphoma whose cancer has returned or progressed after standard care. The goal is to find a safe dose and learn whether it can shrink tumors or help control disease.
This Phase 1 trial tests a new medicine (HG381) in people with advanced solid tumors to see how safe it is and how it works in the body. It may help if standard treatments have already stopped working or aren’t possible for you.
This early-phase trial tests NB002, a new immune-targeting medicine, to find safe doses and see how well it can treat advanced or metastatic solid cancers that have not responded to standard treatments. It may help by strengthening the immune system’s ability to fight the tumor.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.